InMode Ltd. (NASDAQ:INMD – Get Free Report) has been given an average rating of “Hold” by the six analysts that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $22.60.
A number of brokerages have recently issued reports on INMD. Barclays decreased their target price on InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Monday, October 14th. BTIG Research began coverage on shares of InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price objective for the company. Canaccord Genuity Group cut their target price on shares of InMode from $21.00 to $16.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Jefferies Financial Group cut shares of InMode from a “buy” rating to a “hold” rating and decreased their price target for the stock from $21.00 to $19.00 in a research report on Tuesday, July 23rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Thursday, October 10th.
Hedge Funds Weigh In On InMode
InMode Stock Up 2.3 %
Shares of INMD opened at $18.35 on Friday. InMode has a fifty-two week low of $14.87 and a fifty-two week high of $26.80. The company’s fifty day moving average is $16.38 and its two-hundred day moving average is $17.38. The firm has a market cap of $1.54 billion, a PE ratio of 8.70 and a beta of 2.17.
InMode (NASDAQ:INMD – Get Free Report) last issued its earnings results on Thursday, August 1st. The healthcare company reported $0.34 earnings per share for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.04). The firm had revenue of $102.60 million during the quarter, compared to analyst estimates of $104.81 million. InMode had a net margin of 35.81% and a return on equity of 21.00%. InMode’s revenue was down 24.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.65 EPS. As a group, equities research analysts anticipate that InMode will post 1.63 earnings per share for the current year.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Read More
- Five stocks we like better than InMode
- Airline Stocks – Top Airline Stocks to Buy Now
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is a Bond Market Holiday? How to Invest and Trade
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.